Seminars in Oncology Nursing
Volume 23 , Pages 22-35 , February 2007

Nursing Care of Patients Receiving Chemotherapy for Metastatic Colorectal Cancer: Implications of the Treatment Continuum Concept

References 

  1. American Cancer Society. Estimated cancer deaths for selected cancer sites by state, US, 2006. Atlanta, GA: American Cancer Society; 2006;Available at: http://www.cancer.org/downloads/stt/CAFF06EsMcSt.pdf (accessed February 25, 2006)
  2. Meyerhardt JA, Mayer RJ. Systemic therapy for colorectal cancer. N Engl J Med. 2005;352:476–487
  3. Venook A. Critical evaluation of current treatments in metastatic colorectal cancer. Oncologist. 2005;10:250–261
  4. Fuchs C, Hoff P, Saltz L. Recent advances in the treatment of metastatic colorectal cancer. Scientific Updates from the 2006 Gastrointestinal Cancers Symposium. 2006;San Francisco. Sponsored by Pfizer Inc
  5. Kelly H, Goldberg RM. Systemic therapy for metastatic colorectal cancer: Current options, current evidence. J Clin Oncol. 2005;23:4553–4560
  6. Mukherjee S. Gilbert’s syndrome. 2005;Available at: http://www.emedicine.com/med/topic870.htm (accessed March 28, 2006)
  7. Rouits E, Boisdron-Celle M, Dumont A, et al. Relevance of different UFT1A1 polymorphisms in irinotecan-induced toxicity: A molecular and clinical study of 75 patients. Clin Cancer Res. 2004;10:5151–5159
  8. Toffoli G, Cecchin E, Corona , et al. The role of UGT1A1*28 polymorphism in the pharmacodynamics and pharmacokinetics of irinotecan in patients with metastatic colorectal cancer. J Clin Oncol. 2006;24:3061–3068
  9. US Food and Drug Administration. FDA clears genetic test that advances personalized medicine test, helps determine safety of drug therapy. Bethesda, MD: Food and Drug Administration; 2006. 2006;Available at: http://www.fda.gov/bbs/topics/NEWS/2005/NEW01220.html (Accessed February 25, 2006)
  10. Extermann M, Chen H, Cantor AB, et al. Predictors of tolerance to chemotherapy in older cancer patients: A prospective pilot study. Eur J Cancer. 2002;38:1466–1473
  11. Balducci L, Yates J. General guidelines for the management of older patients with cancer. Oncology. 2000;14:221–227
  12. Viale PH. Expanded treatment options in the adjuvant therapy of colon cancer: Implications for oncology nurses. Oncol Nurs Forum. 2006;33:81–90
  13. Saltz L. Understanding and managing chemotherapy-induced diarrhea. J Support Oncol. 2003;1:35–46
  14. National Comprehensive Cancer Network; 2006. National Comprehensive Cancer Network clinical practice guidelines in oncology: antiemesis, v1. 2006;Available at: http://www.nccn.org/professionals/physician_gls/PDF/antiemesis.pdf (accessed March 4, 2006)
  15. National Cancer Institute; 2006. Common terminology criteria for adverse events, v3. 0(CTCAE). 2003;Available at: www.ctep.cancer.gov/forms/CTCAEv.3pdf (accessed April 9, 2006)
  16. Xeloda patient information. Nutley, NJ: Roche Laboratories Inc; 2006;Available at. http://www.rocheusa.com/products/xeloda (accessed Sept 13, 2006)
  17. Benson A, Ajani A, Catalano R, et al. Recommended treatment guidelines for the treatment of cancer treatment-induced diarrhea. J Clin Oncol. 2004;22:2918–2926
  18. Abigerges D, Armand JP, Chabot GG, et al. Irinotecan (cpt-11) high-dose escalation using intensive high-dose loperamide to control diarrhea. J Nat Cancer Inst. 1994;86:446–449
  19. Engelking C. Cancer treatment-related diarrhea: Challenges and barrier to clinical practice. Oncol Nurs Updates. 1998;5:1–15
  20. Wilkes G. Therapeutic options in the management of colon cancer: 2005 update. Clin J Oncol Nurs. 2005;9:31–43
  21. Eloxatin (oxaliplatin for injection). Sanofi-Aventis, Bridgewater, NJ, 2006. Available at: www.eloxatin.com (accessed March 4, 2006)
  22. Viale P, Fung A, Zitella L. Advanced colorectal cancer: Current treatment and nursing management with economic considerations. Clin J Oncol Nurs. 2005;9:541–552
  23. Taieb S, Trillet-Lenoir V, Rambaud L, et al. Lhermitte’s sign and urinary retention. Cancer. 2002;94:2434–2440
  24. Hausheer F, Schilisky R, Bain S, et al. Diagnosis, management, and evaluation of chemotherapy-induced peripheral neuropathy. Semin Oncol. 2006;33:15–39
  25. Gamelin L, Boisdron-Celle M, Delva R, et al. Prevention of oxaliplatin-related neurotoxicity by calcium and magnesium infusions: A retrospective study of 161 patients receiving oxaliplatin combined with 5-fluouracil and leucovorin for advanced colorectal cancer. Clin Cancer Res. 2004;10:4055–4061
  26. Cassidy J, Bjarnason GA, Hickish T, et al. Randomized double blind (DB) placebo (Plcb) controlled phase III study assessing the efficacy of Xaliproden (X) in reducing the cumulative peripheral sensory neuropathy (PSN) induced by the oxaliplatin (Ox) and 5-FU/LV combination (FOLFOX4) in 1st line treatment of patients (pts) with metastatic colorectal cancer (mCRC). (abstr 3507) J Clin Oncol. 2006;24(suppl):
  27. Xaliproden reduces occurrence of severe peripheral sensory neuropathy associated with oxaliplatin-based regimen. Medical News Today. 2006. Available at: http://www.medicalnewstoday.com/medicalnews.php?newsid=38300&nfid=rssfeeds (accessed March 29, 2006)
  28. Lassere Y, Hoff P. Management of hand-foot syndrome in patients treated with capecitabine (Xeloda). Eur J Oncol Nurs. 2004;8(suppl 1):S31–S40
  29. Lin EH, Morris J, Chau NK, et al. Celecoxib attenuated capecitabine induced hand-and-foot syndrome (HFS) and diarrhea and improved time to tumor progression in metastatic colorectal cancer [abstr 2364]. Proc Am Soc Clin Oncol. 2002;21:138b
  30. Nagore E, Insa A, Sanmartin O. Antineoplastic therapy-induced palmar-plantar erythrodysesthesia (“hand-foot”) syndrome: Incidence, recognition and management. Am J Clin Dermatol. 2000;1:225–234
  31. Hoff P, Abbruzzese J, Pluda J. Therapeutic principles of gastrointestinal neoplasia: Emerging therapies: antiangiogenic and antimetastatic agents. In:  Abbruzzese J,  Evans D,  Willett C, et al. editor. Gastrointestinal Oncology. New York: Oxford University Press; 2004;p. 121–126
  32. Avastin. Genentech, South San Francisco, CA, 2005. Available at: www.gene.com/gene/production/information/oncology/avastin/inser.jsp#warnings (accessed March 11, 2006)
  33. Martel CL, Presant CA, Ebrahimi B, et al. Bevacizumab-related toxicities: Association of hypertension and proteinuria. Commun Oncol. 2006;3:90–93
  34. Pande AU, Lombardo JC, Fakih M, et al. Bevacizumab (BV) induced hypertension (HT): A manageable toxicity [abstr 13539]. Proc Am Soc Clin Oncol. 2006;24:318s
  35. Gordon MS, Cunningham D. Managing patients treated with bevacizumab combination therapy. Oncology. 2005;69(suppl 3):25–33
  36. Zondor ST, Medina PJ. Bevacizumab: An angiogenesis inhibitor with efficacy in colorectal and other malignancies. Ann Pharmacother. 2004;38:1258–1264
  37. Motl S. Bevacizumab in combination chemotherapy for colorectal and other cancers. Am J Health-Syst Pharm. 2005;62:1021–1032
  38. Nygren P, Sorbye H, Osterlund P, et al. Targeted drugs in metastatic colorectal cancer with special emphasis on guidelines for the use of bevacizumab and cetuximab: An Acta Oncologica expert report. Acta Oncol. 2005;44:203–217
  39. Yamamoto DS, Viale PH, Zhao G. Severe acneiform rash. Clin J Oncol Nurs. 2004;8:654–656
  40. Frieze DA, McCune JS. Current status of cetuximab for the treatment of patients with solid tumors. Ann Pharmacother. 2006;40:241–250
  41. Khoukaz T. Administration of anti-EGFR therapy: A practical review. Semin Oncol. 2006;22:20–27
  42. Waknine Y. FDA safety changes: Erbitux, risperdal, relafen (Medscape Medical News). 2006;Available at: http://www.medscape.com/viewarticle/518601_print (accessed March 29, 2006)
  43. Waknine Y. Erbitux linked to risk of infusion reactions, hypomagnesemia (Medscape). 2006;Available at: http://www.medscape.com/viewarticle/512947 (accessed March 29, 2006)
  44. Dick S, Crawford G. Managing cutaneous side effects of epidermal growth factor receptor (HER1/EGFR) inhibitors. Commun Oncol. 2005;2:492–496
  45. Peréz-Soler R, Saltz L. Cutaneous adverse effects with HER1/EGRF-targeted agents: Is there a silver lining?. J Clin Oncol. 2005;23:5235–5246
  46. Peréz-Soler R, Delord JP, Halpern A, et al. HER1/EGFR inhibitor-associated rash: Future directions for management and investigation outcomes from the HER1/EGFR Inhibitor Rash Management Forum. Oncologist. 2005;10:245–356
  47. Segaert S, Van Cutsem E. Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. Ann Oncol. 2005;16:1425–1433
  48. Suh KY, Kindler HL, Medenica M, et al. Doxycycline for the treatment of paronychia induced by the epidermal growth factor receptor inhibitor cetuximab. Br J Dermatol. 2005;154:191–192
  49. US Food and Drug Administration, September 2006. Available at: www.fda.gov/cder/foi/label/2006/125147lbl.pdf (accessed October 11, 2006).
  50. Thomas RR, Quin MG, Schuler B, et al. Hypersensitivity and idiosyncratic reactions to oxaliplatin. Cancer. 2003;97:2301–2307
  51. Mis L, Fernando N, Hurwitz H, et al. Successful desensitization to oxaliplatin. Ann Pharmacother. 2005;39:966–969
  52. Gamon D, Bhargava P, McCormick M. Hypersensitivity reactions to oxaliplatin and the application of a desensitization protocol. Oncologist. 2004;9:546–549
  53. Lim KH, Huang MJ, Lin HC, et al. Hypersensitivity to oxaliplatin: A case report and the success of a continuous infusional desensitization schedule. Anticancer Drugs. 2004;15:605–607
  54. Ener RA, Meglathery SB, Styler M. Extravasation of systemic hemato-oncological therapies. Ann Oncol. 2004;15:858–862
  55. Kretzschmar A. Extravasations of oxaliplatin. J Clin Oncol. 2003;21:4066–4069
  56. Sorich J, Taubes B, Wagner A, et al. Oxaliplatin: Practical guideline for administration. Clin J Oncol Nurs. 2004;8:251–255
  57. In:  Polovich M,  White J,  Kelleher L editor. Chemotherapy and Biotherapy Guidelines and Recommendations for Practice. Ed 2. Pittsburgh, PA: Oncology Nursing Society; 2005;p. 68–69
  58. Chan R, Kerr D. Can we individualise chemotherapy for colorectal cancer?. Ann Oncol. 2004;15:996–999
  59. Allen WL, Johnston PG. Role of genomic markers in colorectal cancer treatment. J Clin Oncol. 2005;23:4545–4552
  60. Gasparini G, Longo R, Torino F, et al. Tailored therapy of colorectal cancer: Results, challenges and future directions. Cancer J. 2005;11:175–188

PII: S0749-2081(06)00113-6

doi: 10.1016/j.soncn.2006.08.003

Seminars in Oncology Nursing
Volume 23 , Pages 22-35 , February 2007

Article Tools